Payment overview · 2025
General Payments
$64,174.05
198 reported records · 6 companies
Healthcare provider profile · identity verified
Marcos Daccarett, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · BOISE, ID · NPI 1023144300
Verified facts
What the public records show
CMS Open Payments records show Marcos Daccarett, MD received $64,174.05 in general payments during 2025 across 198 reported records.
Boston Scientific Corporation accounted for 98.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 31 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $63,361.69 | 98.7% | 186 | 2025 |
| Biosense Webster, Inc. | Unresolved — no canonical attribution shown | $539.37 | 0.8% | 5 | 2025 |
| Ethicon US, LLC | Unresolved — no canonical attribution shown | $129.69 | 0.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $73.22 | 0.1% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$63.72 | 0.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $6.36 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,687.50 | 53 |
| Consulting Fee | $5,312.50 | 2 |
| Food and Beverage | $4,810.91 | 130 |
| Travel and Lodging | $4,363.14 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - EP Normalized: general ep |
Device | Boston Scientific Corporation | $46,939.56 | 76 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $11,029.72 | 20 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $2,811.94 | 11 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $512.90 | 2 | 2025 |
Source payment records
|
|||||
| VersaCross Steerable Access Solution Normalized: versacross steerable access solution |
Device | Boston Scientific Corporation | $486.96 | 24 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $477.86 | 19 | 2025 |
Source payment records
|
|||||
| CARTO 3 Normalized: carto 3 |
Device | Biosense Webster, Inc. | $408.69 | 3 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $380.67 | 10 | 2025 |
Source payment records
|
|||||
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $221.64 | 8 | 2025 |
Source payment records
|
|||||
| General - Tachy Normalized: general tachy |
Device | Boston Scientific Corporation | $188.18 | 4 | 2025 |
Source payment records
|
|||||
| NUVISION ICE CATHETER Normalized: nuvision ice catheter |
Device | Biosense Webster, Inc. | $130.68 | 2 | 2025 |
Source payment records
|
|||||
| DERMABOND PRINEO Normalized: dermabond prineo |
Device | Ethicon US, LLC | $129.69 | 1 | 2025 |
Source payment records
|
|||||
| ETHICON Normalized: ethicon |
Device | Ethicon US, LLC | $129.69 | 1 | 2025 |
Source payment records
|
|||||
| MONOCRYL Normalized: monocryl |
Device | Ethicon US, LLC | $129.69 | 1 | 2025 |
Source payment records
|
|||||
| STRATAFIX Normalized: stratafix |
Device | Ethicon US, LLC | $129.69 | 1 | 2025 |
Source payment records
|
|||||
| VISTASEAL Normalized: vistaseal |
Biological | Ethicon US, LLC | $129.69 | 1 | 2025 |
Source payment records
|
|||||
| Electrophysiology Cable Normalized: electrophysiology cable |
Device | Boston Scientific Corporation | $108.82 | 1 | 2025 |
Source payment records
|
|||||
| IntellaMap Orion Normalized: intellamap orion |
Device | Boston Scientific Corporation | $48.33 | 1 | 2025 |
Source payment records
|
|||||
| ASSURITY Normalized: assurity |
Device | Abbott Laboratories | $46.27 | 2 | 2025 |
Source payment records
|
|||||
| AFFERA MAPPING SYSTEM Normalized: affera mapping system |
Device | Medtronic, Inc. | $45.26 | 1 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $38.22 | 3 | 2025 |
Source payment records
|
|||||
| LABSYSTEM PRO Normalized: labsystem pro |
Device | Boston Scientific Corporation | $37.97 | 1 | 2025 |
Source payment records
|
|||||
| TRICLIP Normalized: triclip |
Device | Abbott Laboratories | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| VersaCross Access Solution Normalized: versacross access solution |
Device | Boston Scientific Corporation | $21.57 | 1 | 2025 |
Source payment records
|
|||||
| EMBLEM MRI S-ICD Normalized: emblem mri s icd |
Device | Boston Scientific Corporation | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ATTAIN COMMAND + SUREVALVE Normalized: attain command surevalve |
Device | Medtronic, Inc. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| LATITUDE Communicator Power Supply Normalized: latitude communicator power supply |
Device | Boston Scientific Corporation | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| INGEVITY MRI Normalized: ingevity mri |
Device | Boston Scientific Corporation | $11.37 | 1 | 2025 |
Source payment records
|
|||||
| MetriQ Foot Switch Normalized: metriq foot switch |
Device | Boston Scientific Corporation | $8.60 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $6.36 | 1 | 2025 |
Source payment records
|
|||||
| Maestro 3000 Normalized: maestro 3000 |
Device | Boston Scientific Corporation | $3.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 437 | 184 |
| Clopidogrel | Clopidogrel Bisulfate | 149 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 127 | 59 |
| Flecainide Acetate | Flecainide Acetate | 124 | 66 |
| Amiodarone Hcl | Amiodarone Hcl | 95 | 60 |
| Digoxin | Digoxin | 81 | 35 |
| Warfarin Sodium | Warfarin Sodium | 78 | 33 |
| Sotalol | Sotalol Hcl | 64 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 31 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 60 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 55 |
| Mupirocin | Mupirocin | 56 | 56 |
| Tramadol Hcl | Tramadol Hcl | 49 | 49 |
| Xarelto | Rivaroxaban | 36 | 15 |
| Dofetilide | Dofetilide | 24 | suppressed |
| Carvedilol | Carvedilol | 23 | 13 |
| Lisinopril | Lisinopril | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | 11 |
| Mexiletine Hcl | Mexiletine Hcl | 16 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 13 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Multaq | Dronedarone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64,174.05 · 198 records | Boston Scientific Corporation | ACCOLADE SR, AFFERA MAPPING SYSTEM, ASSURITY, ATTAIN COMMAND + SUREVALVE, CARTO 3, DERMABOND PRINEO, EMBLEM MRI S-ICD, ETHICON, Electrophysiology Cable, FARAPULSE, General - EP, General - Tachy, General - Therapies, INGEVITY MRI, IntellaMap Orion, LABSYSTEM PRO, LATITUDE Communicator Power Supply, LUX-Dx Insertable Cardiac Monitor, LifeVest, MONOCRYL, Maestro 3000, MetriQ Foot Switch, NUVISION ICE CATHETER, Rhythmia Mapping System, STRATAFIX, TRICLIP, VISTASEAL, VersaCross Access Solution, VersaCross Steerable Access Solution, WATCHMAN Access System, WATCHMAN FLX | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error